• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Thailand·Consumer Cyclical·BIS.BK
Share

Bioscience Animal Health Public Company Limited Stocks

THB 2.14Last Updated 27.07.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

THB 20.49M

THB 2.14
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Based in Nonthaburi, Thailand, Bio Science Animal Health Public Company Limited (BIS.BK) is a Thai firm engaged in the distribution of animal pharmaceuticals, feed additives, and raw materials. It serves the livestock, aquaculture, and pet sectors across Thailand. The company's comprehensive product range includes bioscience offerings such as antibiotics, various additives, injectable solutions, mold inhibitors, water-soluble formulations, and vaccines. Furthermore, it provides feed additives, disinfectants, amino acids, essential medical supplies, diagnostic instruments, and a full line of animal health and nutrition products. This enterprise was founded in 2004.

Company Valuation

Undervalued
6/7

Considering past and projected metrics, the stock is 'cheaper' than its peers. Specifically, the stock is fairly valued on P/E, overvalued on EV/EBITDA, underpriced on P/

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

29.07.2026 18:09

Oil prices soared 7% after Trump's remarks about a U.S. retaliatory strike against Iran

29.07.2026 18:00

British "anti-tech stocks" surged to a historic high amid a chip sell-off

29.07.2026 17:42

"Bans Won't Help": Zuckerberg Urged the U.S. Not to Block Chinese Neural Networks

29.07.2026 17:20

Hermès shares fell to a three-year low due to weak performance in China

29.07.2026 15:27

Morning in New York: The Market Awaits a Turning Point

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026